Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Boston Consulting Group
Boston Consulting Group
Activities:
Media
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
You need to be a subscriber to read this article.
Click here
to find out more.
Regulatory
Government reforms will radically change China pharma market
A policy document released alongside the Third Plenary meeting of top Communist Party leaders in Beijing will have systemic consequences for pharma manufacturing and distribution
Research & Development
Partnership will invest US$230m to find new ways to target hard-to-treat diseases
Initiative aims to speed up discovery of new treatments for these illnesses
Media
India should aim to maximise life sciences r&d, says report
By encouraging greater investment and activity in bioinformatics, applied and translational research
Subscribe now